OSU 6162

Drug Profile

OSU 6162

Alternative Names: Movement disorder therapeutics - Pfizer; PNU-96391; PNU-96391A

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Carlsson Research AB
  • Developer Carlsson Research AB; NeuroSearch; Pfizer
  • Class Antipsychotics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor modulators; Dopamine D2 receptor partial agonists; Serotonin 2 receptor modulators; Serotonin 2A receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic fatigue syndrome
  • Discontinued Parkinson's disease

Most Recent Events

  • 04 Feb 2016 OSU 6162 is still in phase II trials for Chronic fatigue syndrome in Sweden
  • 08 Jan 2014 Carlsson Research initiates enrolment in a phase II trial for Chronic fatigue syndrome in Sweden (EudraCT2013-002545-10)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top